Digital evaluation of tumor microenvironment immune markers pre- and post-neoadjuvant pembrolizumab in muscle-invasive bladder cancer (Pure-01 trial: An open label, single arm, phase II study). This ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results